Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Apixaban vs Rivaroxaban in Severe COVID-19
NCT05088928Phase 2Unknown
- Sponsor
- Scotmann Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apixaban in coronavirus disease 2019 (COVID-19), sponsored by Scotmann Pharmaceuticals. Status: unknown.
02
Drugs
apixaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05088928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088928.